About Acura Pharmaceuticals (OTCMKTS:ACUR)
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolOTCMKTS:ACUR
CUSIP00509L70
Phone847-705-7709
Debt
Debt-to-Equity Ratio0.44%
Current Ratio1.23%
Quick Ratio1.23%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.46 million
Price / Sales2.43
Cash FlowN/A
Price / CashN/A
Book Value$0.10 per share
Price / Book5.20
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,380,000.00
Net Margins-36.20%
Return on Equity-231.18%
Return on Assets-31.56%
Miscellaneous
Employees15
Outstanding Shares20,800,000
Acura Pharmaceuticals (OTCMKTS:ACUR) Frequently Asked Questions
What is Acura Pharmaceuticals' stock symbol?
Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."
How were Acura Pharmaceuticals' earnings last quarter?
Acura Pharmaceuticals (OTCMKTS:ACUR) posted its quarterly earnings data on Monday, November, 13th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. The specialty pharmaceutical company had revenue of $0.08 million for the quarter. Acura Pharmaceuticals had a negative return on equity of 231.18% and a negative net margin of 36.20%. View Acura Pharmaceuticals' Earnings History.
What price target have analysts set for ACUR?
0 equities research analysts have issued 12-month target prices for Acura Pharmaceuticals' shares. Their forecasts range from $0.58 to $0.58. On average, they expect Acura Pharmaceuticals' stock price to reach $0.58 in the next year. View Analyst Ratings for Acura Pharmaceuticals.
Who are some of Acura Pharmaceuticals' key competitors?
Some companies that are related to Acura Pharmaceuticals include Bio-Path (BPTH), Cellectar Biosciences (CLRB), Sonoma Pharmaceuticals (SNOA), Prana Biotechnology (PRAN), ESSA Pharma (EPIX), Cyclacel (CYCC), Fibrocell (FCSC), Xenetic Biosciences (XBIO), Ritter Pharmaceuticals (RTTR), Soligenix (SNGX), OHR Pharmaceutical (OHRP), RXi Pharmaceuticals (RXII), Onconova Therapeutics (ONTX), EpiCept (IMNP), Dare Bioscience (DARE), EyeGate Pharma (EYEG), Auris Medical (EARS) and Anthera Pharmaceuticals (ANTH).
Who are Acura Pharmaceuticals' key executives?
Acura Pharmaceuticals' management team includes the folowing people:
- Mr. Robert B. Jones, Pres, CEO & Director (Age 59)
- Mr. Peter A. Clemens, Sr. VP, CFO & Sec. (Age 65)
- Dr. Albert W. Brzeczko Ph.D., VP of Technical Affairs (Age 61)
- Mr. James F. Emigh R.PH., VP of Corp. Devel. (Age 62)
- Mr. Robert A. Seiser Ph.D., VP, Treasurer & Corp. Controller (Age 54)
Has Acura Pharmaceuticals been receiving favorable news coverage?
Press coverage about ACUR stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acura Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 47.22 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Acura Pharmaceuticals?
Shares of ACUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acura Pharmaceuticals' stock price today?
One share of ACUR stock can currently be purchased for approximately $0.52.
How big of a company is Acura Pharmaceuticals?
Acura Pharmaceuticals has a market capitalization of $10.81 million and generates $4.46 million in revenue each year. Acura Pharmaceuticals employs 15 workers across the globe.
How can I contact Acura Pharmaceuticals?
Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]
MarketBeat Community Rating for Acura Pharmaceuticals (ACUR)
MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acura Pharmaceuticals (OTCMKTS:ACUR) Earnings History and Estimates Chart
Acura Pharmaceuticals (OTCMKTS ACUR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | Q3 2017 | | ($0.12) | | $0.08 million | View | N/A |  |
| 8/14/2017 | Q2 2017 | ($0.11) | ($0.18) | | $0.09 million | View | N/A | |
| 5/12/2017 | Q1 2017 | ($0.11) | $0.03 | $0.34 million | $2.72 million | View | N/A | |
| 3/31/2017 | Q4 2016 | ($0.27) | $0.13 | $0.26 million | $3.77 million | View | N/A | |
| 11/14/2016 | Q3 | ($0.27) | ($0.19) | $0.23 million | $0.22 million | View | N/A | |
| 8/8/2016 | Q2 | ($0.28) | ($0.28) | $0.19 million | $0.26 million | View | N/A | |
| 5/2/2016 | Q116 | ($0.26) | ($0.28) | $0.15 million | $0.22 million | View | N/A | |
| 2/29/2016 | Q315 | ($0.03) | ($0.08) | $2.70 million | $2.68 million | View | Listen | |
| 11/4/2015 | Q3 2015 | | ($0.23) | $3.10 million | $0.21 million | View | N/A | |
| 8/3/2015 | Q215 | ($0.02) | ($0.05) | $2.90 million | $0.34 million | View | N/A | |
| 5/4/2015 | Q115 | $0.07 | $0.03 | $7.60 million | $5.40 million | View | N/A | |
| 3/2/2015 | Q414 | ($0.09) | ($0.06) | $0.05 million | $0.53 million | View | N/A | |
| 11/3/2014 | Q3 2014 | ($0.08) | ($0.06) | $0.05 million | $0.15 million | View | N/A | |
| 8/4/2014 | Q2 2014 | ($0.40) | ($0.35) | $0.05 million | $0.04 million | View | N/A | |
| 5/5/2014 | Q1 2014 | | ($0.40) | | $0.04 million | View | N/A | |
| 3/3/2014 | Q4 13 | ($0.06) | ($0.29) | | $0.04 million | View | N/A | |
| 11/4/2013 | Q3 2013 | ($0.35) | ($0.35) | $0.03 million | $0.08 million | View | N/A | |
| 8/1/2013 | Q2 2013 | | ($0.07) | | | View | N/A | |
| 5/2/2013 | Q1 2013 | | ($0.45) | | | View | N/A | |
| 3/4/2013 | Q4 2012 | | ($0.86) | | | View | N/A | |
| 11/6/2012 | Q3 2012 | | ($0.20) | | | View | N/A | |
| 7/30/2012 | Q2 2012 | | ($0.25) | | | View | N/A | |
| 5/1/2012 | Q1 2012 | | ($0.25) | | | View | N/A | |
| 3/5/2012 | Q4 2011 | | ($0.17) | | | View | N/A | |
| 10/31/2011 | Q3 2011 | | ($0.25) | | | View | N/A | |
| 7/28/2011 | Q2 2011 | | $1.78 | | | View | N/A | |
| 4/28/2011 | Q1 2011 | | ($0.31) | | | View | N/A | |
| 3/1/2011 | Q4 2010 | | ($0.31) | | | View | N/A | |
| 11/2/2010 | Q3 2010 | | ($0.27) | | | View | N/A | |
| 7/29/2010 | Q2 2010 | | ($0.34) | | | View | N/A | |
| 4/21/2010 | Q1 2010 | | ($0.45) | | | View | N/A | |
| 3/2/2010 | Q4 2009 | | ($0.44) | | | View | N/A | |
| 10/26/2009 | Q3 2009 | | ($0.43) | | | View | N/A | |
| 7/30/2009 | Q2 2009 | ($0.15) | ($0.71) | | | View | N/A | |
| 5/1/2009 | Q1 2009 | ($0.30) | ($0.14) | | | View | N/A | |
| 3/2/2009 | Q4 2008 | | ($0.07) | | | View | N/A | |
| 10/28/2008 | Q3 2008 | | $0.32 | | | View | N/A | |
| 7/30/2008 | Q2 2008 | | $1.40 | | | View | N/A | |
| 4/30/2008 | Q1 2008 | | $0.75 | | | View | N/A | |
| 3/5/2008 | Q4 2007 | | ($0.01) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Acura Pharmaceuticals (OTCMKTS:ACUR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Acura Pharmaceuticals (OTCMKTS ACUR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 9.41%
Acura Pharmaceuticals (OTCMKTS ACUR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/14/2017 | Bruce F Wesson | Director | Buy | 335,734 | $0.10 | $33,573.40 | 394,404 | |
| 12/14/2017 | Claudius Llc | Major Shareholder | Sell | 2,195,734 | $0.10 | $219,573.40 | | |
| 12/14/2017 | Peter A Clemens | VP | Buy | 300,000 | $0.10 | $30,000.00 | 355,182 | |
| 12/14/2017 | Robert B Jones | Insider | Buy | 400,000 | $0.10 | $40,000.00 | 412,555 | |
| 8/29/2017 | Albert W Brzeczko | VP | Buy | 10,800 | $0.47 | $5,076.00 | 6,200 | |
| 6/17/2015 | Claudius Llc | Major Shareholder | Sell | 104,823 | $1.08 | $113,208.84 | | |
| 1/12/2015 | Claudius Llc | Major Shareholder | Sell | 171,000 | $0.62 | $106,020.00 | | |
| 5/22/2014 | William G Skelly | Director | Sell | 4,600 | $1.23 | $5,658.00 | | |
| 5/20/2014 | William G Skelly | Director | Sell | 5,000 | $1.21 | $6,050.00 | | |
| 5/19/2014 | Albert W Brzeczko | VP | Buy | 2,000 | $1.20 | $2,400.00 | | |
| 5/16/2014 | Bruce F Wesson | Director | Buy | 80,000 | $1.13 | $90,400.00 | | |
| 5/16/2014 | James F Emigh | VP | Buy | 15,000 | $1.21 | $18,150.00 | | |
| 5/16/2014 | Peter A Clemens | CFO | Buy | 3,000 | $1.21 | $3,630.00 | | |
| 5/14/2014 | William G Skelly | Director | Sell | 2,900 | $1.21 | $3,509.00 | | |
| 5/12/2014 | William G Skelly | Director | Sell | 5,000 | $1.25 | $6,250.00 | | |
| 5/8/2014 | William G Skelly | Director | Sell | 2,500 | $1.30 | $3,250.00 | | |
| 3/3/2014 | Claudius Llc | Major Shareholder | Sell | 2,500 | $2.00 | $5,000.00 | | |
| 2/28/2014 | Claudius Llc | Major Shareholder | Sell | 351,260 | $2.02 | $709,545.20 | | |
| 2/24/2014 | Claudius Llc | Major Shareholder | Sell | 44,019 | $1.97 | $86,717.43 | | |
| 11/25/2013 | Albert W Brzeczko | VP | Buy | 1,215 | $1.70 | $2,065.50 | | |
| 10/10/2013 | Claudius Llc | Major Shareholder | Sell | 4,200 | $2.05 | $8,610.00 | | |
| 8/27/2013 | William G Skelly | Director | Sell | 2,000 | $1.55 | $3,100.00 | | |
| 7/15/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 31,610 | $2.04 | $64,484.40 | | |
| 7/3/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 14,200 | $2.00 | $28,400.00 | | |
| 7/2/2013 | Claudius Llc | Major Shareholder | Sell | 200,000 | $2.15 | $430,000.00 | | |
| 6/27/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 76,281 | $2.01 | $153,324.81 | | |
| 6/24/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 83,000 | $2.03 | $168,490.00 | | |
| 6/19/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 114,000 | $2.12 | $241,680.00 | | |
| 6/17/2013 | Claudius Llc | Major Shareholder | Sell | 20,446 | $2.15 | $43,958.90 | | |
| 6/14/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 90,000 | $2.16 | $194,400.00 | | |
| 6/11/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 102,000 | $2.19 | $223,380.00 | | |
| 6/10/2013 | Claudius Llc | Major Shareholder | Sell | 21,496 | $2.20 | $47,291.20 | | |
| 6/6/2013 | Claudius Llc | Major Shareholder | Sell | 39,453 | $2.19 | $86,402.07 | | |
| 6/3/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 148,000 | $2.24 | $331,520.00 | | |
| 5/31/2013 | Claudius Llc | Major Shareholder | Sell | 31,559 | $2.25 | $71,007.75 | | |
| 5/29/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 108,701 | $2.33 | $253,273.33 | | |
| 5/28/2013 | William G Skelly | Director | Sell | 2,000 | $2.40 | $4,800.00 | | |
| 5/23/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 252,000 | $2.31 | $582,120.00 | | |
| 5/22/2013 | William G Skelly | Director | Sell | 4,000 | $2.33 | $9,320.00 | | |
| 5/21/2013 | Claudius Llc | Major Shareholder | Sell | 47,410 | $2.30 | $109,043.00 | | |
| 5/20/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 510,000 | $2.36 | $1,203,600.00 | | |
| 5/16/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 662,000 | $2.38 | $1,575,560.00 | | |
| 5/16/2013 | William G Skelly | Director | Sell | 3,000 | $2.25 | $6,750.00 | | |
| 5/15/2013 | Claudius Llc | Major Shareholder | Sell | 183,434 | $2.33 | $427,401.22 | | |
| 5/13/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 259,000 | $2.19 | $567,210.00 | | |
| 5/9/2013 | William G Skelly | Director | Sell | 3,000 | $2.20 | $6,600.00 | | |
| 4/11/2013 | Claudius Llc | Major Shareholder | Sell | 121,454 | $2.23 | $270,842.42 | | |
| 3/26/2013 | Care Capital Ii Llc | Major Shareholder | Sell | 39,554 | $2.17 | $85,832.18 | | |
(Data available from 1/1/2013 forward)
Acura Pharmaceuticals (OTCMKTS ACUR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Financial Survey: Acura Pharmaceuticals (ACUR) and ACADIA Pharmaceuticals (ACAD)
www.americanbankingnews.com - March 20 at 3:19 AM |
 | Global Respiratory Drugs Market Briefing 2018 - Anti-Asthmatics and COPD Drugs, Cough and Cold Preparations - ResearchAndMarkets.com
www.bizjournals.com - February 3 at 9:22 AM |
| Acura Pharmaceuticals (ACUR) Price Target Lowered to $0.58 at S&P Equity Research
www.americanbankingnews.com - January 17 at 5:24 PM |
 | Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
finance.yahoo.com - January 17 at 3:38 PM |
 | Global Respiratory Drugs Market Briefing 2017 - Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations ... - Business Wire (press release)
www.businesswire.com - January 3 at 3:38 PM |
| Claudius Llc Sells 2,195,734 Shares of Acura Pharmaceuticals, Inc. (ACUR) Stock
www.americanbankingnews.com - January 3 at 12:30 AM |
| Acura Pharmaceuticals (ACUR) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - December 30 at 11:18 AM |
| Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:18 PM |
| Acura Pharmaceuticals, Inc. (ACUR) VP Buys $30,000.00 in Stock
www.americanbankingnews.com - December 15 at 6:54 PM |
| Insider Buying: Acura Pharmaceuticals, Inc. (ACUR) Insider Buys 400,000 Shares of Stock
www.americanbankingnews.com - December 15 at 6:54 PM |
| Acura Pharmaceuticals, Inc. (ACUR) Director Buys $33,573.40 in Stock
www.americanbankingnews.com - December 15 at 6:54 PM |
| Head to Head Survey: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) vs. Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 14 at 5:40 PM |
| Financial Review: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 13 at 7:24 PM |
| Head-To-Head Review: Acura Pharmaceuticals (ACUR) and Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
www.americanbankingnews.com - December 13 at 3:28 AM |
| Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Critical Survey
www.americanbankingnews.com - December 12 at 3:24 AM |
| Head-To-Head Contrast: Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
www.americanbankingnews.com - December 11 at 9:30 PM |
| Reviewing Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 11 at 5:38 AM |
| Comparing Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 10 at 7:20 PM |
| Financial Survey: Acura Pharmaceuticals (ACUR) versus Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
www.americanbankingnews.com - December 10 at 12:14 PM |
| Financial Survey: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 10 at 3:26 AM |
| Head to Head Analysis: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 9 at 3:14 AM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) versus Acura Pharmaceuticals (ACUR) Critical Analysis
www.americanbankingnews.com - December 7 at 7:46 PM |
| Contrasting Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 7 at 5:30 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR) Financial Contrast
www.americanbankingnews.com - December 6 at 11:31 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) vs. Acura Pharmaceuticals (ACUR) Head to Head Analysis
www.americanbankingnews.com - December 6 at 11:30 PM |
| Comparing Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 6 at 7:26 PM |
| Head-To-Head Contrast: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 5 at 3:32 AM |
| Comparing Acura Pharmaceuticals (ACUR) & Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
www.americanbankingnews.com - December 4 at 7:42 PM |
| Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Financial Contrast
www.americanbankingnews.com - December 1 at 5:40 AM |
| Analyzing Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - December 1 at 3:34 AM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR) Head to Head Review
www.americanbankingnews.com - November 29 at 10:08 PM |
| Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Head-To-Head Comparison
www.americanbankingnews.com - November 29 at 7:30 AM |
| Head-To-Head Survey: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - November 28 at 5:20 PM |
| Reviewing Acura Pharmaceuticals (ACUR) & Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
www.americanbankingnews.com - November 28 at 7:56 AM |
| Head to Head Review: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - November 27 at 11:44 PM |
| Acura Pharmaceuticals (ACUR) and Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Head to Head Contrast
www.americanbankingnews.com - November 27 at 11:26 AM |
| Head-To-Head Contrast: Avadel Pharmaceuticals (AVDL) versus Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - November 26 at 4:14 AM |
| Head-To-Head Analysis: Avadel Pharmaceuticals (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - November 26 at 3:48 AM |
| Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals PLC. (AVDL) Head to Head Review
www.americanbankingnews.com - November 24 at 3:56 AM |
| Acura Pharmaceuticals (ACUR) and Avadel Pharmaceuticals PLC. (AVDL) Financial Contrast
www.americanbankingnews.com - November 23 at 1:30 AM |
| Financial Review: Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals PLC. (AVDL)
www.americanbankingnews.com - November 21 at 1:34 PM |
| Contrasting Avadel Pharmaceuticals PLC. (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - November 20 at 3:46 PM |
| Analyzing Acura Pharmaceuticals (ACUR) & Avadel Pharmaceuticals PLC. (AVDL)
www.americanbankingnews.com - November 19 at 5:52 AM |
| Acura Pharmaceuticals (ACUR) & Avadel Pharmaceuticals PLC. (AVDL) Head to Head Survey
www.americanbankingnews.com - November 15 at 1:24 AM |
Acura Pharmaceuticals (OTCMKTS:ACUR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Acura Pharmaceuticals (OTCMKTS:ACUR) Income Statement, Balance Sheet and Cash Flow Statement
Acura Pharmaceuticals (OTCMKTS ACUR) Stock Chart for Monday, April, 23, 2018
Loading chart…
